Expanding the frontiers of synthetic lethality
Better molecules, by design
Evariste is an AI-enabled Drug Discovery company
We develop small molecule therapeutics targeting
synthetic lethal pathways in oncology
Novel Targets
We discover novel synthetic lethal targets and biomarkers, tailoring treatment to underserved patients in an industry fixated on the same old approaches
Better Molecules
Our automated modeling designs high quality, differentiated small molecule candidates at unprecedented scale, speed, and efficiency
Frobenius is Evariste's AI drug discovery platform
Using Frobenius, we de-risk and progress projects with unrivaled efficiency
Each stage of our platform has been validated in challenging internal and collaborative projects
Frobenius Target
Identification of Novel Synthetic Lethal Targets and Biomarkers
We integrate multi-modal data to identify novel drug targets and biomarkers, with an internal focus on synthetic lethal relationships in oncology.
Our proprietary algorithms analyze large public and proprietary multi-omic datasets to uncover actionable targets, which are validated in disease-relevant models to ensure clinical relevance and guide patient stratification.
This approach has led to the discovery of multiple novel synthetic lethal targets with early validation and biomarkers for existing targets, alongside the creation of a clinically-annotated dataset for cancers with high unmet need, paving the way for next-generation therapies.
Frobenius Discovery
Small Molecule Drug Design
We start by combining advanced techniques — from trillion-compound virtual screens to covalent fragments — with our proprietary algorithms to identify novel hits, including for undrugged target families.
Our machine learning models are designed to excel at working with small, noisy datasets. They enable us to conduct efficient design and scoring of small molecules at an unparalleled scale. After finding initial hits, we use probabilistic modeling for multi-parameter optimization across potency, selectivity, and pharmacokinetics to prioritize drug candidates for testing to minimize preclinical risks.
This integrated approach, leveraging both wet-lab and in silico data, has achieved best-in-class potency and selectivity in fewer than 50 compounds, delivering a roughly 10-fold potency increase for every 30 compounds tested.
Using Frobenius, we have developed a pipeline of precision oncology therapeutics
Our pipeline features best-in-class inhibitors of validated synthetic lethal (SL) targets expanded to new indications, and first-in-class inhibitors of novel SL targets
Discovery
Optimization
Enabling
NSCLC, CRC, OC
GBM
AML, DLBCL
.png)
PKMYT1 inhibitor
Targeting PKMYT1 drives synthetic lethality in cancer cells with high replication stress. We have identified and validated a novel biomarker for PKMYT1 with an expanded and differentiated patient population, and nominated development candidate EVT-3023, which is well-tolerated and efficacious in multiple tumor models.
VRK1 inhibitor
VRK1 inhibition is synthetic lethal with VRK2 under-expression. We have identified and validated this synthetic lethal relationship, implicating VRK1 as a highly ranked target in glioblastoma and neuroblastoma. There are no clinical competitors for this target, and we have designed potent inhibitors optimized for CNS permeability.
Novel SL Target
Undisclosed metabolic enzyme target for heavily pretreated hematological malignancies. We have identified a new synthetic lethal target present in a subset of acute myeloid leukemia and diffuse large B-cell lymphoma patients, as well as in HR-deficient solid tumors. We have designed the first ever inhibitors for this target.
We are an exceptional, multidisciplinary team with expertise spanning drug discovery, mathematics, and AI
Anna graduated pre-med from Northwestern University as a neuroscience major. Post pre-med, she studied computer science. She previously helped businesses implement digital tools at a tech consulting company. She now applies her background knowledge in both computer science, business and science to run Evariste.
.png)
Anna Hercot
CHIEF EXECUTIVE OFFICER
Alfie received a PhD in Medicinal Chemistry from Newcastle University, where he worked on fragment based drug discovery. He then moved to the Institute of Cancer Research, working on lead optimization of PPI inhibitors. Alfie has worked on a variety of targets including kinases, bromodomains, sulfatases, PPIs, and E3 ligases.
Alfie Brennan
CHIEF SCIENTIFIC OFFICER
Oliver studied for his Mathematics PhD at Oxford. He worked on developing new data analytic tools to describe the topology and geometry of data sets with interesting spatial structure, as well as the asymptotic topological properties of random simplicial complexes. Oliver develops statistically robust models applied to drug discovery.
Oliver Vipond
HEAD QUANT
Tracy has a PhD in Endocrinology from the University of Edinburgh and a MBA from Quantic School of Business and Technology. After the exciting field of AI enticed her from academia, Tracy worked at BenevolentAI in operations and programme management. She uses her scientific and business background to implement Evariste’s business goals.
Tracy Mak
DIRECTOR OF OPERATIONS
We are advised by a board of world-class scientists and visionary leaders, each bringing unparalleled expertise and commitment to Evariste
Mike Waring is Chair of Medicinal Chemistry at Newcastle University and Head of Chemistry for the Cancer Research UK Newcastle Drug Discovery Unit and Director of the EPSRC Centre for Doctoral Training in Molecular Sciences. He was Principal Scientist in Medicinal Chemistry at AstraZeneca, where he led the TagrissoⓇ chemistry teams. He is a highly experienced medicinal chemist with a track record of delivering drug-discovery projects through the clinic.
.png)
Mike Waring
SCIENTIFIC DIRECTOR
Olivia Rossanese is Director of Drug Discovery and Head of Division for Cancer Therapeutics at the Institute of Cancer Research (ICR), and was previously a member of GSK’s TafinlarⓇ discovery team. Olivia has extensive experience leading and contributing to discovery and target validation programmes, as well as identification of tool molecules, lead compounds, clinical candidates.
.png)
Olivia Rossanese
SCIENTIFIC DIRECTOR
Ollie Watson received his PhD in Number Theory from University of Pennsylvania and has since worked in finance at D. E. Shaw and Tudor Capital, where he led a quantitative research team. He is an expert on optimization and statistical modeling in low signal-to-noise environments, and has taught courses on fitting predictive Bayesian models on noisy data.
Oliver Watson
CHAIRMAN OF THE BOARD
Xavier Jacq currently serves as the CSO of Moa Technology. He was Co-founder of Mission Therapeutics, former VP of Biology at Almac Discovery, and former SVP at Dunad Therapeutics. With over 20 years of experience in the biotech industry, Xavier has been instrumental in driving innovative research and development in the field of therapeutic discovery.
.jpg)
Xavier Jacq
SCIENTIFIC DIRECTOR
Contact us
Evariste is always looking for partners interested in collaborations that utilize our platforms, or licensing deals for our innovative pipeline assets.
We also welcome enquires from investors who wish to join us on our journey to transform drug discovery and the field of synthetic lethality.
News & updates
Stay updated with Evariste's blogposts
.png)
.png)
